All In Biotech

Drug Trial Radar · NCT01349348

Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites

A Randomized, Double-blinded, Multicenter, Placebo Controlled, Parallel Designed Study, to Evaluate the Efficacy and Safety of Tolvaptan Tablet in Treatment of Patients With Cirrhosis Ascites, Using Diuretics as Initial Treatment

Last checked: Nov 20, 2026Latest source record: Oct 12, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 535 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

535

Actual

Start

Oct 2010

Primary completion

May 2012

Study completion Jul 2012

Sponsor

Sponsor type
Industry
First posted
May 6, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of Tolvaptan 7.5mg and 15mg in treatment of patients with cirrhosis ascites who fail to response adequately to treatment with common diuretics.

Conditions

  • Ascites
  • Hepatic Cirrhosis

Interventions

  • TolvaptanDrug

    tablet, 15 mg, Qd, for 7 days

  • TolvaptanDrug

    tablet, 7.5 mg, Qd, for 7 days

  • placeboDrug

    tablet, 7.5/15mg , Qd, 7days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in body weight after 7 days randomized treatment (Day 8).Time frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Renji Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.